Fu, Quan, Zhao, Ma, Jiang, Zhang, Li, Zhang, Meng, Ai, Zhu, Chen, Liu, & Liu (2026). Disturbed flow induced targeting of nanomedicine to endothelial cells for effective atherosclerosis therapy.. Cardiovascular research.
Fu, Quan, Zhao, Ma, Jiang, Zhang, et al. Disturbed flow induced targeting of nanomedicine to endothelial cells for effective atherosclerosis therapy.. Cardiovascular research. 2026; PMID: 42121368
Fu, Quan, Zhao, et al. Disturbed flow induced targeting of nanomedicine to endothelial cells for effective atherosclerosis therapy.[J]. Cardiovascular research. 2026.
@article{fu2026,
author = {Fu and Quan and Zhao and Ma and Jiang and Zhang and Li and Zhang and Meng and Ai and Zhu and Chen and Liu and Liu},
title = {Disturbed flow induced targeting of nanomedicine to endothelial cells for effective atherosclerosis therapy.},
journal = {Cardiovascular research},
year = {2026},
note = {PMID: 42121368},
}
TY - JOUR AU - Fu AU - Quan AU - Zhao AU - Ma AU - Jiang AU - Zhang AU - Li AU - Zhang AU - Meng AU - Ai AU - Zhu AU - Chen AU - Liu AU - Liu TI - Disturbed flow induced targeting of nanomedicine to endothelial cells for effective atherosclerosis therapy. T2 - Cardiovascular research PY - 2026 AN - PMID:42121368 ER -
Atherosclerotic plaques preferentially form at the vascular bifurcations and inner curvature of the aortic arch, where oscillatory shear stress (OSS) induces endothelial cell (EC) inflammation, which is a key driver of disease progression. Given that endothelial cell inflammation is the primary initiating factor, using nanoparticles for site-specific drug delivery may facilitate precise therapeutic intervention. We aimed to determine whether use of a STRN3-derived Hippo-activating peptide (SHAP) laden silicasome (SLS) nanocarrier (SHAP-SLS) possessed the ability to inhibit EC activation and protect against atherosclerosis induced by disturbed flow.